Sanofi-Aventis Collaborates with Dyadic International on Cl Gene Expression

Proof of concept research collaboration to explore the use of C1 technology in vaccine production.

Dyadic International is a Florida-based biotechnology company developing a proprietary C1 gene expression platform that it hopes will speed up the development of less expensive biologic drugs and vaccines. The gene expression system is based on the fungus Myceliophthora thermophila, which is referred to as C1. The C1 system is suitable for the production of proteins at large scale using less costly production processes.

Dyadic is using its C1 technology for the development of virus-like particles (VLPs) and antigens for human and animal vaccines, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters and other therapeutic proteins.

Recently Dyadic announced a new collaboration with Sanofi-Aventis focused on exploring the application of its C1 technology for the production of different types of vaccines and biologic drugs. Sanofi-Aventis will fund the joint research project, which will involve the expression of different genes relevant to vaccine and drug manufacturing using Dyadic’s patented C1 Gene Expression Platform Technology, and is expected to be completed in the second half of 2019.


The goal of the project is to “overcome specific gene expression challenges and to further demonstrate the potential of C1 to become a platform of choice for manufacturing protein-based biologics because of its speed of development and low cost of goods,” according to Dyadic CEO Mark Emalfarb.

Cynthia A. Challener, Ph.D.

Dr. Challener is an established industry editor and technical writing expert in the areas of chemistry and pharmaceuticals. She writes for various corporations and associations, as well as marketing agencies and research organizations, including That’s Nice and Nice Insight.